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Abstract The German National Cohort (GNC) is a joint
interdisciplinary endeavour of scientists from the Helm-
holtz and the Leibniz Association, universities, and other
research institutes. Its aim is to investigate the causes for
the development of major chronic diseases, i.e. cardio-
vascular diseases, cancer, diabetes, neurodegenerative/-
psychiatric diseases, musculoskeletal diseases, respiratory
and infectious diseases, and their pre-clinical stages or
functional health impairments. Across Germany, a random
sample of the general population will be drawn by 18
regional study centres, including a total of 100,000 women
and 100,000 men aged 20–69 years. The baseline assess-
ments include an extensive interview and self-completion
questionnaires, a wide range of medical examinations and
the collection of various biomaterials. In a random sub-
group of 20 % of the participants (n = 40,000) an inten-
sified examination (‘‘Level 2’’) programme will be
performed. In addition, in five of the 18 study centres a
total of 30,000 study participants will take part in a mag-
netic resonance imaging examination programme, and all
of these participants will also be offered the intensified
Level 2 examinations. After 4–5 years, all participants will
be invited for a re-assessment. Information about chronic
disease endpoints will be collected through a combination
of active follow-up (including questionnaires every
2–3 years) and record linkages. The GNC is planned for an
overall duration of 25–30 years. It will provide a major,
central resource for population-based epidemiology in
Germany, and will help to identify new and tailored
strategies for early detection, prediction, and primary pre-
vention of major diseases.
Keywords Population-based cohort  Non-communicable
diseases  Chronic infections  Life-style and socio-
economic factors  Magnetic resonance imaging 
Pre-clinical disease  Functional impairments
Introduction
Over the last 30 years, life expectancy has continuously
improved, in part explained by a downwards trend in inci-
dence rates of cardiovascular diseases and by improved
clinical care for cardiovascular and other chronic diseases.
Nonetheless, cardiovascular diseases and cancer, in partic-
ular, remain the by far most important causes of mortality,
accounting for about 70 % of all deaths in Germany. Fur-
thermore, the increases in overall life expectancy in Ger-
many have been only partially matched by increases in
expected life years free of disease-related disabilities [1].
Due to demographic changes the numbers of patients with
stroke, chronic respiratory diseases, cancer, and neurologic
or psychiatric disorders such as dementia and depression are
increasing. Among the younger generations, an increasing
prevalence of obesity is leading to growing numbers of
patients with early-onset type-II diabetes mellitus [1].
Finally, chronic infections (e.g. viral hepatitis or human
papillomavirus) and various diseases that may result from
them, represent an often under-estimated burden in Ger-
many and other industrially developed countries [1].
A full list of institutions and scientists collaborating in the GNC
consortium is given in the acknowledgements section.
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The abovementioned diseases constitute an increasing
burden on the health care system, and also cause major
losses in working capacity and related costs to the economy
(cf. e.g. ‘‘Gesundheitsberichterstattung des Bundes’’ http://
www.gbe-bund.de/). Health economic analyses suggest
that disease prevention is a cost-effective way of improving
general public health, even when medical costs in addi-
tional life years gained are taken into account [2, 3], and
therefore prevention research remains an area of high pri-
ority for Germany. Effective strategies for the prevention
of chronic diseases require accurate data about the causes
of these diseases and about the potential magnitude by
which chronic disease occurrences can be reduced by
avoiding major risk factors.
Large, population-based prospective cohorts provide the
ideal design for research on the combined effects of life-
style, occupation and environment, social and psychosocial
factors and genetic predisposition on disease development.
A major challenge for such cohorts, however, is that they
need to be very large, so as to allow for statistically
powerful analyses on diverse disease outcomes. Given the
high financial cost of a large-scale prospective cohort study
as a national research infrastructure, it is of fundamental
importance to plan and build the study from a multidisci-
plinary research perspective, and to allow a large number
of medical and life science researchers from various
research institutions, both nationally and internationally, to
have access to the study resource.
The German National Cohort (GNC) builds on the
experience of other medium-sized cohort studies like
Cardiovascular Disease, Living and Ageing in Halle
(CARLA), European Prospective Investigation into Cancer
and Nutrition in Heidelberg und Potsdam (EPIC), Koop-
erative Gesundheitsforschung im Raum Augsburg
(KORA), Heinz Nixdorf Recall Study (HNR, Risk Factors,
Evaluation of Coronary Calcification, and Lifestyle in the
Ruhr area) and Study of Health In Pomerania in Greifswald
(SHIP), and the German National Health Examination
Survey (GNIHES) [4–9]. Furthermore, the GNC study
group collaborates with other large new cohorts, such as
the UK-BIOBANK, CONSTANCES (France) or the
LIFEGENE study [10–12] and major efforts are being
made to harmonise instruments for data collection so as to
allow future joint and comparative analyses.
Study objectives
The GNC is designed to address research questions con-
cerning a broad range of potential causes of major disease
groups. The repeated collection of biomaterials in
combination with extensive information from question-
naires and medical examinations is a basic asset of its
design. The combination of these sources of informa-
tion—repeated over time—will make it possible to spe-
cifically address pathways of disease development,
providing clues to the biological mechanisms that may
explain observed relationships. Overall, four general
objectives are pursued by the National Cohort, and within
their general scope a number of more specific research
questions will be of particular focus.
Identification of etiological pathways from life-style
and environmental risk factors to major chronic diseases
and functional impairments
A first set of specific aims is to increase understanding of
the role of particular risk factors in the development of
major forms of chronic disease, with special emphasis on
selected lifestyle factors (smoking, alcohol consumption,
physical in-activity, nutrition, nutritional energy balance),
as well as chronic infections, psychosocial factors, occu-
pational and environmental influences and use of medica-
tions as possible causes. Using repeated measurements
over time, it is aimed to obtain improved quantitative
estimates for importance of major risk factors in terms of
etiological and population-attributable fractions. In addi-
tion, and by integrating questionnaire data with various
medical or functional examinations (Table 1) and analyses
in bio-specimens, it is aimed to obtain novel insights into
the natural history and causal pathways of disease
development.
Assessment of the geographic and socio-economic
disparities in health status and disease risks in Germany
and possible causes and explanations
A major objective of the GNC is to increase our knowledge
about the fundamental causes for social and regional dis-
parities in health. In addition to risk factors with a potential
direct implication in disease aetiology from a biological,
i.e. ‘‘mechanistic’’ perspective, special emphasis will also
be given to socio-economic position (e.g., education,
income, occupational status) and psychosocial factors (e.g.,
personality traits, chronic stress, workplace social envi-
ronment) as health determinants. Furthermore, using sec-
ondary data sources (e.g. from health insurance records),
information will be collected on the use of health services,
specialised care, hospital care, medical interventions, and
medication as important correlates of socio-economic
inequalities in disease occurrence.
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Improvement of risk prediction models for identifying
individuals at increased risk of developing major chronic
diseases, so as to allow personalised prevention strategies
Risk prediction models and algorithms for stratification of
individuals into categories of lower and higher risk of
developing major chronic diseases are important tools for
personalised medicine and personalised prevention strat-
egies [13–15]. The National Cohort will provide an out-
standing resource for studies aiming to develop and/or
validate comprehensive risk models that integrate risk
factor information obtained by questionnaires, clinical
examinations, whole-body magnetic resonance imaging
(MRI), and the assessment of genetic and other biological
markers in blood, urine and other bio-specimens
(Table 3).
Evaluation of markers for early detection of diseases
and pre-clinical phenotypes, as to develop effective tools
for disease prevention
Detection of pre-clinical stages of diseases may increase
cure rates, and/or help to minimize negative side-effects of
treatment as well as help prevent the occurrence of incident
disease. Stimulated by recent technological advances in the
fields of genomics, transcriptomics, proteomics, meta-
bolomics, epigenomics, and MRI, research on bio-markers
of pre-clinical stages of disease is becoming a major theme
for prevention [16–19]. The bio-specimen repository of the
GNC will provide a valuable resource for the discovery and
validation of novel biomarkers for early disease detection,
at the same time ensuring a rapid connection between basic
discovery research and its confirmation and validation in
appropriately designed human population studies.
Study design and methods
Study population and recruitment
The GNC will recruit a total of 200,000 residents in the age
range of 20–69 years at baseline. Study participants will be
recruited through a network of 18 study centres, covering
mainly urban and industrialised areas and some rural
regions throughout Germany. These centres are grouped
into eight clusters working closely together (Fig. 1). Each
centre will recruit a minimum of 10,000 cohort partici-
pants, drawn randomly from compulsory registries of res-
idents in the study areas. The anticipated response rate is
between 40 and 50 %. Currently there is no financial
compensation for participation planned apart from reim-
bursement of travel costs. Participants will be invited to the
local study centre where they will participate in a
standardised, computer-assisted personal face-to-face
interview (CAPI), complete self-administered question-
naires (partially on touch screen computers) and undergo a
number of standardised physical and medical examina-
tions. In addition, they will provide blood, urine samples
and other biomaterials. All participants will receive a
generalised letter of results in the weeks following their
study visit. This letter will include some of the basic test
results (e. a. blood test results, blood pressure data,
anthropometric data, accelerometry data). For the MRI
examinations, we have defined an exhaustive catalogue of
chance findings that should either, or should not, be com-
municated to the study participants, to inform about
potential health problems that would require further med-
ical attention.
Baseline examination and data collection
Data collection comprises two levels of intensity. All
cohort participants will follow a 2.5 h recruitment protocol
including the CAPI and questionnaire assessments and
Table 1 Chronic diseases, pre-clinical phenotypes and functional
measurements that will be ascertained in the German National Cohort
Chronic diseases Intermediate phenotypes and
measurements of function
CVD (myocardial infarction,









MRI), elevated blood pressure
Diabetes mellitus Impaired glucose tolerance
(fasting glucose, oral glucose
tolerance test), accumulation of
advanced glycation end
products in the skin (skin
autofluorescence), retinopathy
(retinal photographs)













nitric oxide, FeNO), lung
volume (MR imaging)
Infectious diseases Seromarkers, immune function
Musculoskeletal diseases Arthrosis, rheumatoid arthritis
(Medical examination of knee,
hip and hand joints)
The German National Cohort 373
123
basic physical and medical examinations (Level 1), and a
random sub-sample of 40,000 participants (20 % per study
centre) will participate in an extended protocol that
includes more in-depth physical and medical examinations
(Level 2). In addition, at five MRI centres—in Augsburg,
Berlin, Essen, Mannheim and Neubrandenburg—a total of
30,000 participants (drawn from the GNC participants of
the respective study centres) will additionally undergo a
high-resolution (3 T) MRI protocol for the acquisition of
whole body, cardiac, and brain images, generating a
comprehensive morphological and functional data base
(MRI programme). The participants will either pertain to
the random 20 % Level 2 sample or they will be offered the
Level 2 examinations in addition to Level 1. The intensi-
fied sub-cohorts (Level 2 and MRI programme) will be
used for more detailed studies on risk factors and early
clinical precursor stages of diabetes, heart disease, and
neurodegenerative disorders, in particular.
The baseline interview and self-administered question-
naires will cover socio-economic and socio-demographic
factors, medical history, use of medications and health
care, lifestyle factors, and questions related to environ-
mental and occupational factors (Table 2). In addition,
physical and medical examinations will be performed as
specified in Table 3. Finally, all study participants will be
asked to provide samples of blood, urine, saliva and stool,
as well as nasal swabs (Table 3).
Repeat data collections and medical examinations
over time
All participants of the GNC will be re-invited for a sec-
ond examination (re-assessment) 4–5 years after their
baseline recruitment which will include about the same
examinations (except long-term ECG and oral glucose
tolerance test) as at baseline at Level 1 and 2, but with a
reduction in the number of aliquots collected for the bio-
specimens. For the MRI programme, funding has to be
sought for the repeat-examination as the current funding
only covers the baseline MRI examination. At re-assess-
ment, intra-individual, medium-term changes in risk fac-
tors and prospective changes in quantifiable preclinical
morbidity characteristics and incident clinical disease can
be investigated. For the re-assessment, we anticipate a re-
participation rate of at least 75 % of all cohort partici-
pants. This estimate is based on experiences from a
number of ongoing studies in Germany, including KORA
(Augsburg), HNR (Essen), SHIP (Greifswald), CARLA
(Halle) and the German National Health Interview and
Examination Survey 1998 (GNHIES)/DEGS survey for
adults [5–7, 9, 20, 21].
In addition to the re-assessment after 4–5 years, short-
term (0.5-year) replication studies will be embedded in the
cohort, using a 6,000-subject sub-sample of participants of
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participants in the second visit, proportionally spread over
all 18 study centres. These reliability studies will serve to
estimate within-subject ‘‘random’’ variations in risk factor
measurements, so as to allow corrections of attenuation
effects resulting from random misclassification.
Prospective follow up for vital status and case
ascertainment of incident diseases
As from their first enrolment into the GNC, all cohort
participants will be re-contacted every 2–3 years and asked
to fill in short questionnaires about changes in lifestyle and
other characteristics (e.g., use of medications, smoking,
menopausal status, selected disease symptoms) and about
the occurrence of physician-diagnosed diseases or of trig-
gering events for selected major diseases, such as visiting a
cardiologist or having been hospitalised (‘‘active’’ follow-
up). Additional telephone contacts and interviews will be
used for participants who do not respond to written invi-
tations. Self-reported cases of novel onset major diseases
will be verified systematically by contacting the partici-
pant’s pertinent physician(s) and/or hospitals at which they
were treated, and coded according to the International
Classification of Diseases (ICD) [22]. The list of diseases
for which this form of follow-up will be the principal
method of prospective case ascertainment includes coro-
nary heart disease/myocardial infarction, heart failure,
atrial fibrillation, type-2 diabetes mellitus, cerebrovascular
disease (stroke), depression, cancer, and chronic infectious
diseases. With regard to cancer occurrences, follow-up will
also be based on systematic record linkages with existing
epidemiological cancer registries (‘‘passive’’ follow-up),
which are mandatory now and soon will cover all regions
of Germany. For other morbidities, it is planned to com-
plete self-reports by data obtained through linkage to health
insurance records plus systematic queries at large clinics
and hospitals.
With regard to vital status and mortality, follow-up will
be performed through queries to registries of residents and
authorities (‘‘Einwohnermeldea¨mter’’, ‘‘statistische Land-
esa¨mter’’, ‘‘Gesundheitsa¨mter’’). While the latter are
common practice in many epidemiological studies, they are
relatively labour-intensive. A new German National Death
Index (NDI), which is presently being planned (indepen-
dently of the GNC), will make the follow-up for mortality
more efficient in future years.
Linkage to secondary data to obtain additional
information on the individual’s health and employment
history
Data from statutory health insurances
About 85 % of the population in Germany is insured by the
statutory health insurance system, and the GNC is setting
up cooperation structures with data holding institutions to
allow individual data linkage for participants. The health
insurance data contain information about disease diagnoses
and treatment, ambulatory and hospital care and prescribed
medications. The major objective of the linkage of health
insurance data is to obtain information on the use of health
services and medications, for health services research and
research on medications and interventions as possible
determinants of disease outcomes and prognosis. In




Socio-economic status (SES) and socio-demographic factors
Medical history
Family medical history
Medication of the last 7 days
Participation in screening programmes
Women’s/men’s questions
Smoking, alcohol, other drugs
Health-related and other quality of life (e.g. SF-12, IADL)
Specific questionnaires
Neurologic and psychiatric factors (symptom questionnaire,
depression, anxiety disorders, headache, sleep) (MINI, PHQ-9,
PHQ-7, RLS [RLS only Level 2])
Psychosocial factors (personality, chronic stress, childhood
trauma, occupational stress, social network; conflicts at the work
place and in the family, occupational insecurity) (BFI-10, PHQ
stress, ERI, COPSOQ, childhood trauma)
Infections and immune function
Musculoskeletal diseases: Pain mannequin (only Level 2)
Oral health (OHIP-5)
Physical activity (at work, leisure time, and sport; activity patterns,
setting)
Diet (FFQ, 24 h diet recall)
Environmental factors (postal addresses of work and home)
Occupation (screening questions for special exposures at work)
Health care utilization and compliance (GP, specialist
consultation, hospital stays)
Health-related and other quality of life Health survey: SF-12;
Instrumental Activities of Daily Living questionnaire: Amsterdam-
IADL-Questionnaire. Neurologic and psychiatric factors Mini Inter-
national Neuropsychiatric Interview: MINI; Patient Health Ques-
tionnaire: PHQ-7, PHQ-9; Cambridge-Hopkins RLS questionnaire:
CHRLSq. Psychosocial factors The Big Five Inventory: BFI-10;
Patient Health Questionnaire: PHQ-Stress; Effort-reward imbalance
questionnaires: ERI; Copenhagen Psychosocial Questionnaire: CO-
PSOQ. Oral health The Oral Health Impact Profile questionnaire:
OHIP-5. Diet Food Frequency Questionnaire: FFQ. Health care uti-
lization and compliance GP: Patient Survey
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addition, however, the information may be used as an
additional source of information on disease incidence.
Data on occupational history
More than 95 % of the German workforces are member of
the compulsory statutory pension insurance system. These
insurances hold socio-demographic data of the employees,
as occupational code, and job position, provided by the
employer on an at least annual basis. The legal entity that
holds all these data and is allowed (within strict limits) to
use it for research purposes is the Institute for Employment
Research (IAB). The GNC will cooperate with IAB to
augment the data of the participants with respect to occu-
pational history.
Geocoded environmental data
Data on environmental exposures will be generated by the
combination of occupational and home addresses with
available geocoded exposure data, e.g., for air pollution,
background radiation, noise and heat.
Time line
The projected time frame for the National Cohort covers a
period of 25–30 years (Fig. 2). The recruitment will start
with a pilot phase in the 2nd half of 2013. Start of full-scale
recruitment is planned for the beginning of 2014. Shortly
after completion of recruitment, the study centres will start
with the re-assessment of the entire cohort.
Table 3 Physical and medical examinations to be conducted within
the German National Cohort at baseline recruitment, by study level
(Level 2 exams in addition to Level 1 exams)
Study element 1st visit
Level 1 Level 2
Cardiovascular system
Blood pressure and heart rate x x
Electrocardiography (10-s ECG; 12 leads) x x
3D Echocardiography x x
Ankle–brachial index (ABI), measures of
arterial stiffness (pulse wave)
x x
Long-term ECG/apnea device x
Diabetes
Oral glucose tolerance test (OGTT;
n = 40,000 including Level 1 ? 2
participants)
x
AGE reader (skin autofluorescence) x
Cognitive function










Nitric oxide (FeNO) in exhaled air x
Musculoskeletal system
Medical examination of knee, hip and hand
joints for arthrosis and rheumatoid arthritis
x
Oral health
Tooth count x x
Medical examination of the oral cavity for





(retinal photography, simple visus test) x
Hearing test: speech in noise number triple
test (application via touch screen and
headphone)
x
Olfactory test (Sniffin’ sticks 12) x x
Physical activity, physical fitness
7-Day accelerometry x x
Submaximal bicycle ergometry x
Hand grip strength x x
Anthropometry
Body weight and body height (standing) x x
Waist and hip circumference x
Body impedance analysis (BIA) x
Ultrasound of the abdominal fat distribution x
Bio-specimens
Serum 6 ml (30 aliquots)
Table 3 continued
Study element 1st visit
Level 1 Level 2
Plasma 9,6 ml (48 aliquots)
Erythrocytes 1,2 ml (6 aliquots)
Lymphocytes for DNA 2.4 ml (4 aliquots)
RNA tubes 1
Urinea 6 ml (12
aliquots) ? 2,4 ml
(4 aliquots)
Saliva 1.2 ml (2 aliquots)
Nasal swab 2 swabs per tube
Stool 1 tube with DNA
stabilisation
reagent (8 ml)
a Spot urine will be collected during the time the participants are at
the study centre
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Expected case numbers for major chronic diseases,
and statistical power considerations
For a project that has the size and scope of the GNC,
developing a notion of necessary study size is a complex
exercise. Besides the anticipated statistical evaluation for
a great variety of possible study questions, the total
number of study participants planned was also carefully
balanced against the depth of phenotyping and detail of
data collected from the study participants. One basic
guideline was that, with regard to a number of chronic
endpoints such as major forms of cancer and cardio-
vascular diseases, the cohort study should be large
enough to allow future, stand-alone evaluations within
the GNC for basic risk factor associations. For the most
frequent diseases, such as diabetes or myocardial
infarction, the GNC should also allow the development
of detailed, multivariable risk models including large
numbers of potential risk determinants. For rarer forms
of disease or pre-clinical phenotypes the GNC should be
large enough to make a meaningful contribution to
international cohort consortia.
Table 4 presents the expected case numbers for the
most frequent forms of cancer and for selected non-cancer
chronic endpoints. Standard calculations indicate that
studies which include at least 300–500 cases of a specific
disease, with control-to-case ratios varying between 2:1
and 4:1, will have a statistical power of 0.80 (at a sig-
nificance level of 0.05) to detect an odds ratio of about
1.4–1.6 for a binary exposure with 20 % population
prevalence, or an odds ratio of about 1.5–1.7 for top
versus bottom quartile categories of an exposure or risk
factor. The number of 300–500 incident cases of disease
corresponds, for example, to the rarer forms of cancer
listed in Table 4 or to incident cases of type 2 diabetes
among adults \40 years of age in the ‘‘Level 2’’ sub-
cohort with intensified phenotyping. With 1,000–2,500
cases, as obtained for more frequent diseases at both
study levels after 10 years, a statistical power (at signif-
icance level 0.05) of 0.80 or higher is given to detect
exposure-disease associations corresponding to an expec-
ted odds ratio of around 1.15–1.3 between the extreme
quartiles. 1,000–2,500 incident cases are expected to be
observed for the more frequent cancer types, and in the
intensified sub-cohort (N = 40,000) similar case numbers
are also expected for diabetes and common CVD end-
points. At still higher levels of incidence, with 5,000
events and more (e.g., diabetes, frequent forms of car-
diovascular disease and overall mortality), the minimally
detectable odds ratios are even lower, and studies will
have high statistical power also for complex forms of
statistical modelling, e.g. involving interaction terms with
rare exposures (e.g. genetic variants).
For studies of rarer disease outcomes, as well as studies
that require extremely large numbers of endpoints (e.g., for
comprehensive modelling of gene–environment interac-
tions involving genetic variants with low allele frequency)
the GNC consortium will collaborate with other large-scale
Calendar year 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 ………………………………………………. 42
Study year -4 -3 -2 -1 1 2 3 4 5 6 7 8 9 10 11 ………………………………………………. 30
Preparation, pre-tests, and pilot study 
Active follow-up of study participants (disease endpoints)
Mortality follow-up
Follow-up questionnaires for assessment of changes in risk factors
Supply of data and biospecimens for epidemiologic analysis within
the cohort
Baseline assessment - first study visit
Reassessment - second study visit
Fig. 2 Roll-out of the German National Cohort—overall timeline
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At all recruitment centres data will be collected through
web-based, standardised data entry forms and protocols for
interviews and questionnaires as well as for all physical
and medical examinations. The data are directly integrated
in two data integration centres, at the University of Gre-
ifswald and at the German Cancer Research Center
(DKFZ), which will share the task of offering data col-
lection services (including constant on-line support) to the
18 study centres. The 2 integration centres offer identical
services, each to half of the 18 study centres (divided
geographically into a northern and a southern region), and
will ensure continuous mutual back-ups of the full datasets
collected from all 18 centres. Also, at any time both inte-
gration centres will be able to take over each other’s data
collection services, covering the other half of the study
centres as a back-up service.
Prospective record linkage, a master participant index,
and prospective consent management will be performed by
a trusted third party separate from the main study data base.
The trusted third party maintains all linkages to external
secondary data sources and conducts prospective vital
status follow-up.
MRI programme
For the MRI programme, five dedicated GNC MR imaging
centres will be established, with the instalment of new 3-T
MRI devices. Identical equipment is being installed at all
Table 4 Expected counts of incident cancer cases and incident non-cancer cases after 5, 10, 15 or 20 years of average follow-up, for the overall
cohort (N = 200,000) or for the intensified sub-cohort (N * 60,000)
Disease Expected cumulative incidence at study Level 1 (200,000
subjects)
Expected cumulative incidence at study Level 2 (*60,000
subjectsa)

















Any cancer 5,100 13,000 21,000 29,000 1,500 3,900 6,000 9,000
Breast 780 1,800 2,900 4,000 240 555 885 1,200
Prostate 720 1,900 3,200 4,600 210 570 960 1,365
Colon, Rectum 670 1,800 3,100 4,500 195 540 930 1,335
Lung 560 1,400 2,400 3,400 165 435 720 1,020
Bladder 260 710 1,200 1,800 75 210 375 540
Kidney 190 500 850 1,200 60 150 255 360
non-Hodgkin L. 140 340 580 820 45 105 180 240
Pancreas 120 330 580 830 30 105 180 255
Corpus Uteri 120 320 540 770 30 90 165 300
Brain ? CNS 90 200 330 450 30 60 105 135
Ovary 110 260 440 610 30 75 135 180
Myocardial infarction 1,700 4,400 7,300 10,000 525 1,305 2,250 3,150
Stroke 1,600 4,300 7,500 11,000 465 1,290 2,250 3,300
Diabetes 5,800 13,000 21,000 28,000 1,800 4,050 6,300 8,400
Rheum. arthritis 250 590 940 1,300 75 180 285 375
COPD 2,300 5,800 9,700 13,000 690 1,740 2,850 4,050
Heart failure 1,600 4,600 8,200 12,000 480 1,380 2,550 3,600
Mortality 4,600 14,000 26,000 47,000 1,365 4,050 7,950 13,950
Calculations based on age-specific incidence from German Cancer Registries [23]
a 40,000 participants in the representative Level 2 study programme plus *20,000 participants in the MRI study, who will additionally also
have the Level 2 examinations
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these centres, so as to allow the highest possible degree of
standardization of the whole-body MRI examinations in
terms of image quality and internal validity, and for rea-
sons of cost-effectiveness. MRI technologists from each
study site receive centralised training and certification by a
central imaging core. In total, 30,000 subjects will be
examined by MRI, and all subjects undergoing the MRI
programme will also participate in the Level 2
examinations.
To deal with incidental findings, a group of MRI spe-
cialists is currently preparing a list of life-threatening
observations and a final Standard Operating Procedures
(SOP) for their communication. Only these will be com-
municated to the participants.
Collection and storage of bio-specimens
From all cohort participants various bio-specimens will be
collected, i.e., whole blood, serum, EDTA plasma, eryth-
rocytes, RNA, urine, saliva, nasal swabs, stool. To guar-
antee the highest quality of the samples, the collection and
processing of the samples will be highly standardised and
includes the use of an automated liquid handling system for
sample aliquoting. In addition, a detailed and comprehen-
sive bio banking concept was elaborated. Two-thirds of
each individual’s aliquots collected during baseline
recruitment and the subsequent re-assessment will be
stored in a centralised and fully automated bio-repository,
which will be established at the German Centre for Envi-
ronmental Health (HMGU Munich). One-third of each
individual’s biological specimens will be stored at the local
study centres for use in local analyses and as back-up
storage.
Quality management (QM)
To guarantee a high quality of data collection, processing
and storage throughout the GNC, a comprehensive QM
system will be established, including central structures for
internal and external QM. The Robert Koch Institute (RKI)
will be responsible for the external QM, while the internal
QM will be centrally organised by a QM officer based in
the central executive office of the GNC and will conducted
by the study centres themselves. For data collection and
medical examinations standardised instruments will be
applied, and detailed SOPs will be used in all centres. The
study personnel will undergo an extensive training and will
be centrally certified for the complete data collection
including all examinations, application of questionnaires
and recruitment procedures. Repeated centralised training
and recertification will take place at regular intervals.
Ethics and data confidentiality
The GNC will be performed in compliance with the Fed-
eral Data Protection Acts [24] and all other pertinent leg-
islation and directives. Furthermore, the ‘Opinion of the
German Ethics Council’ [25] on human bio-banks for
research as well as other ethically relevant directives will
be observed. The aim is to secure trust into the way data
and bio-samples are stored and handled. A data protection
concept for the GNC was developed in close collaboration
with the German federal and state commissioners for data
protection and freedom of information. An external ethics
advisory board has been established which will accompany
the GNC over the full study period. A ‘Code of Ethics’ of































Fig. 3 Scheme of governance
and management structures of
the German National Cohort
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general rules and principles for ethical collection and use of
study data (www.nationale-kohorte.de), and the study will
be under steady surveillance by the ethical committees of
the regional study centres. Special emphasis will be placed
on privacy, safety of data, especially genetic information
and reporting of incidental medical findings.
Funding, governance and management
As a long-term project and scientific infrastructure, the
GNC needs to secure long-term funding. For the first
10 years, which will cover baseline assessment and re-
assessment of all 200,000 study participants, as well as a
first phase of prospective follow-up for disease occurrence,
the German federal and local state governments and the
Helmholtz Association cover the main part of the overall
budget, and approved a budget plan for the first 10 years of
the project. This will be complemented by considerable in-
kind contributions of all participating institutions.
As a long-term scientific project, with participation of a
large number of institutions, the GNC requires special
governance and management structures. The central gov-
erning body is the formally established GNC e.V. as a
registered association (since February 2013) in which all
participating research institutions are members. The gen-
eral assembly of the association has elected a board of
directors as who will be responsible for the implementation
of the government and management of the GNC, including
four scientific directors and one administrative director. A
commission of funders acts as a supervisory board
regarding general governance questions and project deci-
sions with possible financial impact (Fig. 3).
The society’s general assembly has formed several
committees and working groups, including an epidemio-
logical steering committee (composed of 1–2 scientists per
participating scientific institution), and a working group for
Quality Management. A number of scientific and thematic
working groups, involving many scientists across
Germany, have been very active in developing the GNC
study protocol, and it is planned that these will be con-
tinued as platforms for the planning of scientific use of the
GNC data and bio-specimens. In addition to these internal
organization structures, the GNC receives external guid-
ance by a Scientific Advisory Board and an Ethical Advi-
sory Board.
With regard to the rights of access to and use of study
data and bio-specimens explicit and detailed rules have
been defined, which can be found on the homepage of the
GNC (http://www.nationale-kohorte.de/nutzungsordnung.
html). A use and access committee will review all appli-
cations for the use of data and bio samples of the GNC and
suggest decisions to the General Assembly and the Board
of Directors.
Conclusion
The GNC will provide a central platform for future epi-
demiological research in Germany, with a strong potential
to push the development of new strategies for prevention,
early detection and prognosis of major chronic diseases.
With its broad spectrum of examinations and the system-
atic re-assessments of all study participants, and its broad
spectrum of high-quality biomaterials a cohort of this size
provides an excellent tool for future, population-based
longitudinal research. The large-scale, embedded MRI
programme is another unique asset of the GNC. One spe-
cial element of the GNC is the fact that virtually the whole
German epidemiological community has collaborated in
the design and preparation of the GNC, and many of them
will be directly involved in the field work. The GNC thus
constitutes an extraordinary basis for scientific cooperation
and networking amongst epidemiologists and other health
scientists in Germany.
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